Mark E. Boulding
2017
In 2017, Mark E. Boulding earned a total compensation of $1.1M as Executive Vice President and Chief Legal Officer at PTC Therapeutics, a 42% decrease compared to previous year.
Compensation breakdown
| Bonus | $2,000 |
|---|---|
| Non-Equity Incentive Plan | $164,966 |
| Option Awards | $406,010 |
| Salary | $434,120 |
| Stock Awards | $101,070 |
| Other | $13,743 |
| Total | $1,121,909 |
Boulding received $434.1K in salary, accounting for 39% of the total pay in 2017.
Boulding also received $2K in bonus, $165K in non-equity incentive plan, $406K in option awards, $101.1K in stock awards and $13.7K in other compensation.
Rankings
In 2017, Mark E. Boulding's compensation ranked 8,426th out of 14,666 executives tracked by ExecPay. In other words, Boulding earned more than 42.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 8,426 out of 14,666 | 43rd |
Division Manufacturing | 3,196 out of 5,772 | 45th |
Major group Chemicals And Allied Products | 1,062 out of 2,075 | 49th |
Industry group Drugs | 838 out of 1,731 | 52nd |
Industry Pharmaceutical Preparations | 656 out of 1,333 | 51st |
Source: SEC filing on April 30, 2018.
Boulding's colleagues
We found six more compensation records of executives who worked with Mark E. Boulding at PTC Therapeutics in 2017.
2017
Stuart Peltz
PTC Therapeutics
Chief Executive Officer
2017
Marcio Souza
PTC Therapeutics
Chief Operating Officer
2017
Mark Rothera
PTC Therapeutics
Former Chief Commercial Officer
2017
Neil Almstead
PTC Therapeutics
Executive Vice President, Research, Pharmaceutical Operations & Technology
2017
Christine Utter
PTC Therapeutics
Principal Financial Officer and Treasurer
2017
Shane Kovacs
PTC Therapeutics